PTO-144		11/18/2005 DDUCED		ATTORNEY DOCKET NO. 119P/PCT2/US	APPLICAT	10564240f~1GAU: 1 APPLICATION NO. 10/554,240		
TA OBS	INFO	RMATION DISCLOSURE O		APPLICANT DONG, Zheng Xin				
8 (1002 T	۵)			FILING DATE Oct. 21, 2005		GROUP/EXAMINER Unknown/Unknown		
MARK OF			บ.ร.	PATENT DOCUMENTS				
EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE	
	Α	5,482,698	Jan. 9, 1996	Griffiths				
	В	5,525,338	Jun. 11, 199	Goldenberg				
	С	5,795,909	Aug. 18, 1998	Shashoua et al.				
	D	5,843,903	Dec. 1, 1998	Schally et al.				
	E	5,948,750	Sep. 7, 1999	Garsky et al.				
	F	6,077,499	Jun. 20, 2000	Griffiths et al.				
	G	6,191,290	Feb. 20, 2001	Safavy				
	Н	6,207,660	Mar. 27, 2001	Sessler et al.				
	I	2002 0094964	Jul. 18, 2002	Chen et al.			1	
	J	2002 0115596	Aug. 22, 2002	Garsky et al.				
	K	2003 0064053	Apr. 3, 2003	Liu et al.				
	L	2003 0064984	Apr. 3, 2003	Ng et al.		<u> </u>	1	
	M	2005 0070470	Mar. 31, 2005	Coy et al.	<u> </u>	<u> </u>	· · · · · · · · · · · · · · · · · · ·	
			FOREIGN	PATENT DOCUMENTS				
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO	
	N	96/40210	Dec. 19, 1996	WIPO PCT				
_	0	97/19954	Jun. 5, 1997	WIPO PCT	1			
	Р	02/34237	May 2, 2002	WIPO PCT				
	Q	02/87497	Nov. 7, 2002	WIPO PCT				
	R	0 450 461 (A2, A3, B1)		EP				
	S	0 450 480 (A2, A3, B1)		EP				
	T	1 118 336	Jul. 25, 2001	EP				
		OTHER DOCUMENTS	(Including Au	thor, Title, Date, Perti	nent Pages,	Etc.)		
	U	FUSELIER, et al., "An adjustable release rate linking strategy for cytotoxin-peptide conjugates," Bioor. Med. Chem. Lett., 2003, 10:799-803.						
	V	HUANG, et al., "Targeting delivery of paclitaxel into tumor cells via somatostatin receptor endocytosis," Chem. Biol., 2000, 7:453-461.						
· · · · · · · · · · · · · · · · · · ·	W	KOVACS, et al., "Recovery of pituitary function after treatment with a targeted cytotoxic analog of						
	X	lutenizing hormone-releasing hormone," PNAS, 1997, 94:1420-1425. NAGY, et al., "Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin," PNAS, 95:1794-1799.						
	^`							
	Y	SAFAVY, et al., "Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery," Bioconjug. Chem., 2003, 14:302-310						
		, a grand y , a strong						
EXAMI	MINER /Andrew D. Kosar/ DATE CONSIDERED 08/30/2009							
	-							